tbuckley/cabot-search huggingface dataset:
SAT0053 The Added Value of Ultrasound to Evaluate Remission in Rheumatoid Arthritis: Table 1.
Authors: K. Ben Abdelghani, S. Miladi, S. Kassab, S. Chekili, A. Laatar, L. Zakraoui
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Various definitions of remission in Rheumatoid Arthritis (RA) have been proposed. The Disease Activity Index 28 joints (DAS28) is the routinely used score. Newer tools for evaluation of RA activity include the Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) are available and have proved to be more stringent. <h3>Objectives</h3> The purpose of this study was to compare the accuracy of composite scores of remission in RA patients using the absence of inflammatory activity detected by ultrasound (US) as a gold standard. <h3>Methods</h3> Sixty seven patients followed-up for RA were recruited. B-mode and a Power Doppler (PD) US exam were assessed by a single rheumatologist who was experienced in US and blinded to the clinical and laboratory data. Twenty two joints were scanned (wrists, 10 metacarpophalangeal (MCP) and proximal interphalangeal (PIP)). SDAI and CDAI were calculated for each patient. Sensitivity, specificity and Positive Predictive value (PPV) for each score was calculated with as reference absence of Doppler signal in US. Then ROC curve were analyzed. <h3>Results</h3> Among all patients, 30 were in remission according to the DAS28, 19 according to SDAI and 26 according to CDAI. For 19 patients there was no Doppler signal in US. The sensitivity and specificity of different remission scores considering as reference absence of joints with PD signal is showed in table 1. The ROC curves showed that the best threshold of DAS28 was 3.2. It was 6.5 for SDAI and 8 for CDAI. <h3>Conclusions</h3> Ours results suggest that when considering remission as an absence of Doppler signal, the DAS28 was the most sensitive and the CDAI was the most specific. The ROC curves showed threshold exceeding definition of remission. <h3>References</h3> Balsa A, De Miguel E and col. Superiority of SDAI over DAS-28 in assessing remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard. Rheumatology 2010. <h3>Disclosure of Interest</h3> None declared
Too much medicine in older people? Deprescribing through shared decision making
Authors: Jesse Jansen, Vasi Naganathan, Stacy M Carter, Andrew J McLachlan, Brooke Nickel, Les Irwig, Carissa Bonner, Jenny Doust, Jim Colvin, Aine Heaney, Robin Turner, Kirsten McCaffery
Journal: BMJ (2016)

Jansen and colleagues  explore the role of shared decision making in tackling inappropriate polypharmacy in older adults
<i>Salmonella typhimurium </i>Suppresses Tumor Growth via the Pro-Inflammatory Cytokine Interleukin-1β
Authors: Jung-Eun Kim, Thuy Xuan Phan, Vu Hong Nguyen, Hong-Van Dinh-Vu, Jin Hai Zheng, Misun Yun, Sung-Gyoo Park, Yeongjin Hong, Hyon E. Choy, Michael Szardenings, Won Hwang, Jin-A Park, SunHee Park, Sin-Hyeog Im, Jung-Joon Min
Journal: Theranostics (2015)

Although strains of attenuated Salmonella typhimurium and wild-type Escherichia coli show similar tumor-targeting capacities, only S. typhimurium significantly suppresses tumor growth in mice.The aim of the present study was to examine bacteria-mediated immune responses by conducting comparative analyses of the cytokine profiles and immune cell populations within tumor tissues colonized by E. coli or attenuated Salmonellae.CT26 tumor-bearing mice were treated with two different bacterial strains: S. typhimurium defective in ppGpp synthesis (ΔppGpp Salmonellae) or wild-type E. coli MG1655.Cytokine profiles and immune cell populations in tumor tissue colonized by these two bacterial strains were examined at two time points based on the pattern of tumor growth after ΔppGpp Salmonellae treatment: 1) when tumor growth was suppressed ('suppression stage') and 2) when they began to re-grow ('re-growing stage').The levels of IL-1β and TNF-α were markedly increased in tumors colonized by ΔppGpp Salmonellae.This increase was associated with tumor regression; the levels of both IL-1β and TNF-α returned to normal level when the tumors started to re-grow.To identify the immune cells primarily responsible for Salmonellae-mediated tumor suppression, we examined the major cell types that produce IL-1β and TNF-α.We found that macrophages and dendritic cells were the main producers of TNF-α and IL-1β.Inhibiting IL-1β production in Salmonellae-treated mice restored tumor growth, whereas tumor growth was suppressed for longer by local administration of recombinant IL-1β or TNF-α in conjunction with Salmonella therapy.These findings suggested that IL-1β and TNF-α play important roles in Salmonella-mediated cancer therapy.A better understanding of host immune responses in Salmonella therapy may increase the success of a given drug, particularly when various strategies are combined with bacteriotherapy.
The second chance for advanced Hodgkin's disease.
Authors: G P Canellos
Journal: Journal of Clinical Oncology (1992)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1992.10.2.175 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 1732420 The second chance for advanced Hodgkin's disease. G P CanellosxG P CanellosSearch for articles by this author https://doi.org/10.1200/JCO.1992.10.2.175 First Page PDF © 1992 by American Society of Clinical Oncology
AB0268 Metatarsophalangeal Joint Dislocation has Clinical Impact on Global Functional Impairment in Patients with Rheumatoid Arthritis – a Cross-Sectional Study from Kurama Cohort-
Authors: H. Ito, Y. Hamamoto, M. Furu, M. Hashimoto, T. Fujii, M. Ishikawa, M. Azukizawa, C. Terao, T. Mimori, S. Matsuda
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Forefoot deformity is one of the most dominant deformities in patients with rheumatoid arthritis (RA). However, which deformity has the most clinical relevance on global functional impairment in the lower extremities remains to be investigated. We conducted a cross-sectional study on this subject using a comprehensive RA cohort (KURAMA cohort). <h3>Objectives</h3> To investigate relationship among forefoot deformities and the influence of functional impairment in the lower extremities from a RA cohort. <h3>Methods</h3> A cross-sectional clinical cohort survey was performed on 740 feet of 370 patients with RA in KURAMA cohort. The average age was 62.8 years old, and the female ratio was 87.6%. Radiographic measurements such as hallux valgus angle (HV angle), metatarsal deformities (M1M2 and M1M5 angles), Larsen grade of the metatarsophalangeal joints (MTP joints), and lateral angle and dislocation of MTP joints were obtained along with clinical data such as age, duration of the disease, seropositivity, disease activity and medication. <h3>Results</h3> HV, M1M2, M1M5 angles and lateral angle of MTP joint were significantly correlated each other (p&lt;0.05). The numbers of dislocation of MTP joint were most significantly correlated with HV angle and lateral angle of MTP joint (ρ=0.839, 0.514, respectively), while much less with M1M2 and M1M5 angles (ρ=0.277, 0.135, respectively). On the other hand, HV angle and lateral angle of the MTP joint had significant correlation with duration of disease, Steinbrocker stage, DAS28-ESR, CRP, and HAQ, while M1M2 and M1M5 angles did only with duration of the disease. When functional impairment of the lower extremity (lower HAQ) was exclusively counted among the scores of HAQ, multivariate analyses showed the number of dislocation of MTP joint was a sole independent significant predictor for lower-HAQ. <h3>Conclusions</h3> MTP joint dislocation has the most significant influence on functional impairment in the lower extremities among forefoot deformities in patients with RA. To avoid daily disability, MTP joints should be paid careful attention and be treated appropriately. <h3>Disclosure of Interest</h3> H. Ito Grant/research support from: Takeda, Mitsubishi Tanabe, Chugai, Pfizer, Astellas Pharma, Daiichi Sankyo, Y. Hamamoto: None declared, M. Furu Grant/research support from: Mitsubishi Tanabe, Chugai, Eisai, Bristol-Myers, M. Hashimoto Grant/research support from: Mitsubishi Tanabe, Chugai, Eisai, Bristol-Myers, Astellas Pharma, T. Fujii Grant/research support from: Mitsubishi Tanabe, Chugai, Eisai, Bristol-Myers, M. Ishikawa: None declared, M. Azukizawa: None declared, C. Terao: None declared, T. Mimori: None declared, S. Matsuda: None declared
AB0564 Disease Damage is Associated with Increased Aortic Stiffness in Systemic Lupus Erythematosus: A Cross-Sectional Study
Authors: E. Bartoloni, F. Battista, A. Alunno, G. Pucci, V. Valentini, F. Cannarile, G. Schillaci, R. Gerli
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Increasing evidence suggests that accelerated atherosclerosis accounts for increased morbidity and premature mortality for cardiovascular (CV) disease in systemic lupus erythematosus (SLE) patients (1). Both traditional CV risk factors and disease specific features, including disease activity and damage, have been demonstrated to significantly predict accelerated atherosclerosis. Among indirect measures of subclinical atherosclerosis, aortic stiffness (AS), measured by carotid-femoral pulse wave velocity (cf-PWV), is considered a strong independent risk factor for future CV morbidity and mortality in different clinical settings. Indeed, AS has been demonstrated to be increased in patients with inflammatory diseases with respect to controls (2). To date, few data suggest that SLE patients are characterized by a significantly increased AS with respect to controls. However, factors influencing AS in SLE have not been well defined. <h3>Objectives</h3> To evaluate cf-PWV as a measure of AS in SLE patients and analyze relationship between disease-related features and cf-PWV. <h3>Methods</h3> Forty consecutive SLE patients (90% females, mean age 45±12 years) with median disease duration of 12 years (IQR 5-19) were enrolled. Traditional CV risk factors, overt CV events, disease-specific clinical, metabolic and immunologic features were collected at enrollment. Disease activity and damage were assessed by the SLEDAI and SLICC indexes, respectively. Carotid-femoral PWV was determined by means of applanation tonometry (SphygmoCor). The relationship between cf-PWV and all variables was investigated with univariate (one-way ANOVA) and multivariate models. <h3>Results</h3> Average cf-PWV was 7.5±1.9 m/s mean. Mean blood pressure was 128/75±16/10 mmHg. Nine subjects (23%) were on anti-hypertensive treatment, 4 (10%) reported previous cardiovascular events, 17 (42%) subjects were treated with steroids, 29 (71%) with hydroxychloroquine and 15 (37%) with other immunosuppressants. Median SLEDAI and SLICC indexes were 0 (IQR 0-2) and 2 (IQR 1-3), respectively. Cf-PWV significantly increased across SLICC damage index categories (F=3.141, p&lt;0.019). The association between cf-PVW and SLICC index persisted after adjustment for age, sex, mean arterial pressure, height, heart rate, disease duration, anti-hypertensive treatment, number of drugs for SLE therapy, C-reactive protein and previous cardiovascular events (p=0.031). <h3>Conclusions</h3> Disease damage appears to be a relevant factor influencing functional artery status in SLE. Present results support the need of adequate prevention of disease damage to slow the progression of subclinical atherosclerosis in SLE patients. <h3>References</h3> Bartoloni E et al; Expert Rev Clin Immunol 2007;3:531-41. Schillaci G, Bartoloni E et al; Ann Rheum Dis 2012;71:1151-6. <h3>Disclosure of Interest</h3> None declared
Change in thyroid hormone levels following response to cognitive therapy for major depression
Authors: R Joffe, Z Segal, W Singer
Journal: American Journal of Psychiatry (1996)

Various somatic antidepressant treatments of depression are associated with substantial but limited decreases in T4 levels. This study examined changes in patients' thyroid hormone levels during a period of cognitive behavior therapy.Thyroid hormone levels of 30 patients with major depressive disorder were measured before and after they received 20 weekly sessions of cognitive behavior therapy.There were significant decreases in measures of T4 in the 17 responders to cognitive behavior therapy and increases in the 13 nonresponders.Cognitive behavior therapy has an effect on the thyroid axis similar to that of somatic antidepressant treatments.
Benjamin Franklin
Authors: M. Therese Southgate
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial
Authors: Rafael de la Torre, Susana de Sola, Gimena Hernandez, Magí Farré, Jesus Pujol, Joan Rodriguez, Josep María Espadaler, Klaus Langohr, Aida Cuenca-Royo, Alessandro Principe, Laura Xicota, Nathalie Janel, Silvina Catuara-Solarz, Gonzalo Sanchez-Benavides, Henri Bléhaut, Iván Dueñas-Espín, Laura del Hoyo, Bessy Benejam, Laura Blanco-Hinojo, Sebastiá Videla, Montserrat Fitó, Jean Maurice Delabar, Mara Dierssen
Journal: The Lancet Neurology (2016)
Therapist actions that address initially poor therapeutic alliances in psychotherapy
Authors: S A Foreman, C R Marmar
Journal: American Journal of Psychiatry (1985)

The authors studied six patients treated in time-limited dynamic psychotherapy who had initially poor therapeutic alliance scores; three patients went on to have improved alliances and good outcomes, and three had unimproved alliances and poor outcomes. The therapist actions that most strongly differentiated the two groups and occurred more frequently in the cases with improved alliances and good outcomes were 1) addressing the patient's defenses, 2) addressing the patient's guilt and expectation of punishment, 3) addressing the patient's problematic feelings in relation to the therapist, and 4) linking the problematic feelings in relation to the therapist with the patient's defenses.
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial
Authors: Orly Vardeny, Brian Claggett, Milton Packer, Michael R. Zile, Jean Rouleau, Karl Swedberg, John R. Teerlink, Akshay S. Desai, Martin Lefkowitz, Victor Shi, John J.V. McMurray, Scott D. Solomon
Journal: European Journal of Heart Failure (2016)

Abstract Aims In this analysis, we utilized data from PARADIGM‐HF to test the hypothesis that participants who exhibited any dose reduction during the trial would have similar benefits from lower doses of sacubitril/valsartan relative to lower doses of enalapril. Methods and results In a post‐hoc analysis from PARADIGM‐HF, we characterized patients by whether they received the maximal dose (200 mg sacubitril/valsartan or 10 mg enalapril twice daily) throughout the trial or had any dose reduction to lower doses (100/50/0 mg sacubitril/valsartan or 5/2.5/0 mg enalapril twice daily). The treatment effect for the primary outcome was estimated, stratified by dose level using time‐updated Cox regression models. In the two treatment arms, participants with a dose reduction (43% of those randomized to enalapril and 42% of those randomized to sacubitril/valsartan) had similar baseline characteristics and similar baseline predictors of the need for dose reduction. In a time‐updated analysis, any dose reduction was associated with a higher subsequent risk of the primary event [hazard ratio (HR) 2.5, 95% confidence interval (CI) 2.2–2.7]. However, the treatment benefit of sacubitril/valsartan over enalapril following a dose reduction was similar (HR 0.80, 95% CI 0.70–0.93, P &lt; 0.001) to that observed in patients who had not experienced any dose reduction (HR 0.79, 95% CI 0.71–0.88, P &lt; 0.001). Conclusions In PARADIGM‐HF, study medication dose reduction identified patients at higher risk of a major cardiovascular event. The magnitude of benefit for patients on lower doses of sacubitril/valsartan relative to those on lower doses of enalapril was similar to that of patients who remained on target doses of both drugs.
AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition
Authors: Hannah A. Scarborough, Barbara A. Helfrich, Matias Casás-Selves, Alwin G. Schuller, Shaun E. Grosskurth, Jihye Kim, Aik-Choon Tan, Daniel C. Chan, Zhiyong Zhang, Vadym Zaberezhnyy, Paul A. Bunn, James DeGregori
Journal: Clinical Cancer Research (2016)

Abstract Purpose: The emergence of EGFR inhibitors such as gefitinib, erlotinib, and osimertinib has provided novel treatment opportunities in EGFR-driven non–small cell lung cancer (NSCLC). However, most patients with EGFR-driven cancers treated with these inhibitors eventually relapse. Recent efforts have identified the canonical Wnt pathway as a mechanism of protection from EGFR inhibition and that inhibiting tankyrase, a key player in this pathway, is a potential therapeutic strategy for the treatment of EGFR-driven tumors. Experimental Design: We performed a preclinical evaluation of tankyrase inhibitor AZ1366 in combination with multiple EGFR-inhibitors across NSCLC lines, characterizing its antitumor activity, impingement on canonical Wnt signaling, and effects on gene expression. We performed pharmacokinetic and pharmacodynamic profiling of AZ1366 in mice and evaluated its therapeutic activity in an orthotopic NSCLC model. Results: In combination with EGFR inhibitors, AZ1366 synergistically suppressed proliferation of multiple NSCLC lines and amplified global transcriptional changes brought about by EGFR inhibition. Its ability to work synergistically with EGFR inhibition coincided with its ability to modulate the canonical Wnt pathway. Pharmacokinetic and pharmacodynamic profiling of AZ1366-treated orthotopic tumors demonstrated clinically relevant serum drug levels and intratumoral target inhibition. Finally, coadministration of an EGFR inhibitor and AZ1366 provided better tumor control and improved survival for Wnt-responsive lung cancers in an orthotopic mouse model. Conclusions: Tankyrase inhibition is a potent route of tumor control in EGFR-dependent NSCLC with confirmed dependence on canonical Wnt signaling. These data strongly support further evaluation of tankyrase inhibition as a cotreatment strategy with EGFR inhibition in an identifiable subset of EGFR-driven NSCLC. Clin Cancer Res; 23(6); 1531–41. ©2016 AACR.
Bioinformatics Data Distribution and Integration <i>via</i> Web Services and XML
Authors: Xiao Li, Yizheng Zhang
Journal: Genomics Proteomics & Bioinformatics (2003)

It is widely recognized that exchange, distribution, and integration of biological data are the keys to improve bioinformatics and genome biology in post-genomic era. However, the problem of exchanging and integrating biology data is not solved satisfactorily. The eXtensible Markup Language (XML) is rapidly spreading as an emerging standard for structuring documents to exchange and integrate data on the World Wide Web (WWW). Web service is the next generation of WWW and is founded upon the open standards of W3C (World Wide Web Consortium) and IETF (Internet Engineering Task Force). This paper presents XML and Web Services technologies and their use for an appropriate solution to the problem of bioinformatics data exchange and integration.
Oxygen Nanocarrier for Combined Cancer Therapy: Oxygen‐Boosted ATP‐Responsive Chemotherapy with Amplified ROS Lethality
Authors: Pengfei Zhao, Mingbin Zheng, Zhenyu Luo, Xiujun Fan, Zonghai Sheng, Ping Gong, Ze Chen, Baozhen Zhang, Dapeng Ni, Yifan Ma, Lintao Cai
Journal: Advanced Healthcare Materials (2016)

Oxygen nanocarrier (A/D-ONC) with a polymeric core entrapping hemoglobin and a cationic lipid shell absorbing a DOX-intercalating DNA duplex is developed. After endocytosis oxygenated A/D-ONC donates O2 to cancer cells that acts therapeutically by: (1) increasing intracellular ATP content that promotes DOX release, thereby converting ATP to the trigger of detrimental chemotherapy; (2) by synchronously increasing the ROS amount to amplify the lethality to cancer cells. As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Response to Cortisone and Development of Cortisone Resistance in a Cortisone-Sensitive Lymphosarcoma of the Mouse
Authors: Julia McCain Lampkin, Michael Potter
Journal: JNCI Journal of the National Cancer Institute (1958)

Journal Article Response to Cortisone and Development of Cortisone Resistance in a Cortisone-Sensitive Lymphosarcoma of the Mouse Get access Julia McCain Lampkin, Julia McCain Lampkin Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael Potter Michael Potter Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 20, Issue 6, June 1958, Pages 1091–1111, https://doi.org/10.1093/jnci/20.6.1091 Published: 01 June 1958 Article history Received: 21 November 1957 Published: 01 June 1958